Histone deacetylases govern heterochromatin in every phase.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Transient DNMT3L Expression Reinforces Chromatin Surveillance to Halt Senescence Progression in Mouse Embryonic Fibroblast.Frontiers in cell and developmental biology · 2020
   Article
2. Class-Specific Histone Deacetylase Inhibitors Promote 11-Beta Hydroxysteroid Dehydrogenase Type 2 Expression in JEG-3 Cells.International journal of cell biology · 2017
   Article
3. Spatial segregation of heterochromatin: Uncovering functionality in a multicellular organism.Nucleus (Austin, Tex.) · 2016
   Review
4. Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.Molecular neurobiology · 2015
   Article

Corrections and comments

• Comment on
  Distinct roles for Sir2 and RNAi in centromeric heterochromatin nucleation, spreading and maintenance.2013
• Comment on
  Sir2 is required for Clr4 to initiate centromeric heterochromatin assembly in fission yeast.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as